Chimeric Therapeutics announces new partnership to advance CAR T manufacturing in Australia

August 20, 2024 09:57 AM AEST | By Team Kalkine Media

Google News:

Recent News

Top Entertainment Options in Oahu, Honolulu, Waikiki: What Travelers N...

SYDNEY BASED CBD INSIGHTS LIFESTYLE MAGAZINE COMMENCE FEATURES ON CARP...

At London Climate Week, forestry companies launch Natural Capital Valu...

Apple internally weighs bid for ChatGPT rival Perplexity, Bloomberg sa...

Chimeric Therapeutics (ASX:CHM), a leader in the development of CAR T cell therapies, has entered into a significant partnership with Cell Therapies Pty Ltd (CTPL), a specialist in cellular therapy manufacturing. This collaboration is designed to elevate the landscape of CAR T manufacturing within Australia, positioning the country as a hub for cutting-edge medical advancements. The primary focus of this partnership is to bolster local production capabilities for CAR T cell therapies. By leveraging CTPL's expertise in manufacturing and Chimeric Therapeutics' innovative research and development in the CAR T space, the collaboration aims to streamline the production process. This is expected to not only enhance the efficiency and scalability of manufacturing CAR T cells but also to ensure that these potentially life-saving treatments are more readily available to patients across Australia.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.